• J Laubach, L Garderet, A Mahindra, G Gahrton, J Caers, O Sezer, P Voorhees, X Leleu, H E Johnsen, M Streetly, A Jurczyszyn, H Ludwig, U-H Mellqvist, W-J Chng, L Pilarski, H Einsele, J Hou, I Turesson, E Zamagni, C S Chim, A Mazumder, J Westin, J Lu, T Reiman, S Kristinsson, D Joshua, M Roussel, P O'Gorman, E Terpos, P McCarthy, M Dimopoulos, P Moreau, R Z Orlowski, J S Miguel, K C Anderson, A Palumbo, S Kumar, V Rajkumar, B Durie, and P G Richardson.
• Dana-Farber Cancer Institute, Boston, MA, USA.
• Leukemia. 2016 May 1; 30 (5): 1005-17.

AbstractThe prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and general approach to patients with specific disease characteristics. In addition, the manuscript provides a summary of evidence from clinical trials that have significantly impacted the field, including those evaluating conventional dose therapies, as well as both autologous and allogeneic stem cell transplantation. Specific recommendations are offered for management of first and second relapse, relapsed and refractory disease, and both autologous and allogeneic transplant. Finally, perspective is provided regarding new agents and promising directions in management of relapsed MM.

15 keywords...

hide…